Ebenbichler, Christoph

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., et al. (2025) · European Heart Journal

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 688

Evinacumab in Patients with Refractory Hypercholesterolemia

Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 302

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled, phase 2 trial

von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology

Diabetes and associated disordersPancreatic function and diabetes

Cited by 186

High-fat diet causes iron deficiency via hepcidin-independent reduction of duodenal iron absorption

Sonnweber, T., Ress, C., Nairz, M., Theurl, I., Schroll, A., Murphy, A. T., Wroblewski, V., Witcher, D. R., Moser, P., Ebenbichler, C. F., et al. (2012) · The Journal of Nutritional Biochemistry

Iron Metabolism and DisordersTrace Elements in Health

Cited by 117

Postprandial state and atherosclerosis

Ebenbichler, C. F., Kirchmair, R., Egger, C., & Patsch, J. R. (1995) · Current Opinion in Lipidology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 116

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Effects of weight loss on lipid transfer proteins in morbidly obese women

Laimer, M. W., Engl, J., Tschoner, A., Kaser, S., Ritsch, A., Tatarczyk, T., Rauchenzauner, M., Weiss, H., Aigner, F., Patsch, J. R., et al. (2009) · Lipids

Lipid metabolism and disordersBariatric Surgery and Outcomes

Cited by 28